State Board of Administration of Florida Retirement System Decreases Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

State Board of Administration of Florida Retirement System cut its holdings in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) by 24.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,126 shares of the biopharmaceutical company’s stock after selling 4,580 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Intercept Pharmaceuticals were worth $195,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ICPT. Prospera Financial Services Inc raised its stake in shares of Intercept Pharmaceuticals by 27.2% during the first quarter. Prospera Financial Services Inc now owns 26,033 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 5,565 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Intercept Pharmaceuticals by 13.4% in the first quarter. New York State Common Retirement Fund now owns 19,430 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 2,293 shares during the last quarter. WINTON GROUP Ltd grew its holdings in shares of Intercept Pharmaceuticals by 25.1% in the first quarter. WINTON GROUP Ltd now owns 17,360 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 3,486 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Intercept Pharmaceuticals by 53.7% in the first quarter. JPMorgan Chase & Co. now owns 305,441 shares of the biopharmaceutical company’s stock worth $4,970,000 after purchasing an additional 106,655 shares during the last quarter. Finally, Jupiter Asset Management Ltd. bought a new position in shares of Intercept Pharmaceuticals in the first quarter worth approximately $5,152,000. 86.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Robert W. Baird cut their target price on shares of Intercept Pharmaceuticals from $52.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, October 3rd. B. Riley cut their target price on shares of Intercept Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, August 22nd. Raymond James raised their target price on shares of Intercept Pharmaceuticals from $23.00 to $26.00 and gave the stock an “outperform” rating in a report on Thursday, August 4th. HC Wainwright cut their target price on shares of Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, November 16th. Finally, Piper Sandler cut their price target on shares of Intercept Pharmaceuticals from $82.00 to $49.00 in a report on Friday, September 30th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.80.

Intercept Pharmaceuticals Stock Performance

NASDAQ:ICPT opened at $15.13 on Wednesday. The stock has a market cap of $626.64 million, a P/E ratio of 2.64 and a beta of 1.14. The firm’s fifty day simple moving average is $14.90 and its 200 day simple moving average is $15.47. Intercept Pharmaceuticals, Inc. has a twelve month low of $10.81 and a twelve month high of $21.25. The company has a quick ratio of 2.46, a current ratio of 2.46 and a debt-to-equity ratio of 2.07.

About Intercept Pharmaceuticals

(Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Read More

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.